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2 
Abstract 22 
Background  23 
Prostate cancer (PCa) is one of the leading causes of mortality and morbidity globally, but its 24 
specific geographical patterns and temporal trends are under-researched.   25 
Objective 26 
To test the hypotheses that the incidence of PCa was higher and its mortality was lower in 27 
countries with higher socioeconomic development, and that the temporal trends of incidence 28 
increased whilst mortality decreased with time. 29 
Design, Settings and Participants 30 
Data on age-standardized incidence/mortality rates in 2012 were retrieved from the GLOBOCAN 31 
database.  Temporal patterns were assessed for 36 countries obtained from the Cancer Incidence 32 
in Five Continents volumes I-X and the WHO mortality database.  The correlation between the 33 
incidence/mortality rates and socioeconomic indicators (Human Development Index [HDI] and 34 
Gross Domestic Product [GDP]) was evaluated.   35 
Outcome Measurements and Statistical Analysis  36 
The average annual percent change of PCa incidence and mortality in the most recent 10 years 37 
from join-point regression. 38 
Results and Limitations 39 
Reported incidence rates of PCa varied more than 25-fold worldwide in 2012, with the highest 40 
incidence rates observed in Micronesia/Polynesia, the US and the European countries. The 41 
3 
mortality rates paralleled the incidence rates except for Africa, where the mortality rates were the 42 
highest. Countries with higher HDI (r=0.58) and GDP per capita (r=0.62) reported greater 43 
incidence rates.  Based on figures in the recent 10 years, most countries experienced increases in 44 
incidence, with sharp rise in incidence rates in Asia, Northern and Western Europe.  A substantial 45 
reduction in mortality rates was reported in most countries, except in some Asian countries and 46 
Eastern Europe where mortality increased. Figures in regional registries could be underestimated. 47 
Conclusions 48 
The incidence of PCa increased whilst its mortality decreased in most countries. In countries with 49 
higher socioeconomic development, the reported incidence was higher. 50 
Patient Summary 51 
The PCa incidence had high variation geographically and over time with smaller variations in 52 
mortality. 53 
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4 
Introduction 64 
Prostate cancer (PCa) is the second commonest diagnosed malignancy and the fifth leading cause 65 
of cancer mortality in men, accounting for a substantial public health burden [1]. Currently, the 66 
established risk factors for PCa include advanced age, black race, a family history of the disease, 67 
and certain genetic polymorphisms [2].  There is a strong prospect to reduce PCa induced 68 
mortality by screening [3, 4].  Hence, it is crucial to understand its global epidemiological trends. 69 
 70 
Previous studies describing its international trends were based on figures from registries in early 71 
2000s [5-7], did not take into account the socioeconomic development of each country when 72 
comparisons were made [8, 9], or depended on model-based clustering [10].  Analyzing the 73 
patterns and temporal trends of PCa could quantify geographical variation, identify high-risk 74 
populations and delineate the extent of PSA testing uptake [9].  These epidemiological data could 75 
also be linked to the future prospects of cancer prevention for policy-makers [11]. 76 
 77 
A survey based on the UK regional cancer registry found that a substantial socioeconomic 78 
gradient exists in the use of radiotherapy or surgery in men diagnosed with prostate cancer, as 79 
well as the application of screening tests for PCa [12].  The study calls for further correlations of 80 
the incidence and mortality patterns in countries with various degrees of socioeconomic 81 
development. Therefore, we tested the hypothesis that the incidence and mortality of PCa was 82 
associated with higher and lower levels of socioeconomic development and productivity, 83 
respectively, across different countries.  In addition, a recent study [13] pinpointed a substantial 84 
increase in incidence but decrease in mortality of PCa in the US.  However, it is unknown 85 
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whether similar trends might exist in other countries, and evaluation of its global incidence and 86 
mortality figures is one of the important research perspectives.  Therefore, we sought to test the 87 
hypothesis that its global incidence showed an increasing trend and its mortality decreased in 88 
most countries. 89 
 90 
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Materials and Methods 104 
Source of Data 105 
The incidence and mortality estimates for PCa (ICD-10 C61) were retrieved from the 106 
GLOBOCAN database for 184 countries in 2012 [1].  We made reference to a recent 107 
epidemiological study on colorectal cancer and used similar methodology [11].  We obtained data 108 
on the Human Development Index (HDI) and Gross Domestic Product (GPD) for each country in 109 
2012 from the United Nations Human Development Report [14], which highlights the progress 110 
on human development over the past quarter century by reporting the different statistical indexes. 111 
HDI is a composite index of life expectancy, education period, and income per capita indicators 112 
[14].  We extracted the incidence and mortality figures from GLOBOCAN (2012) for the various 113 
continents (Table 1), and plotted the age-standardized incidence and mortality against HDI and 114 
GDP per capita of the same calendar year (Figures 1a and 1b).  For temporal trend analysis, we 115 
extracted incidence data for the high quality national population-based cancer registries from the 116 
Cancer Incidence in Five Continents (CI5) series Volumes I-X  [15], as well as the WHO 117 
mortality database for mortality data for all 36 countries (Figure 2).  There were 11 countries for 118 
which more comprehensive, updated data were available (as compared with CI5), and hence were 119 
used to replace the data from CI5 (for incidence) and the WHO mortality database (for mortality).  120 
These include the US [16], New Zealand [17], Australia [18], the European Cancer Observatory 121 
[19], and the Nordic Cancer Registries [20]. 122 
The incidence data were allocated into different categories according to the International 123 
Classification of Diseases 10th revision (ICD-10, C61), whereas mortality data were categorized 124 
based on the ICD 9th (185) up to 1991 and 10th version (C61) thereafter.  More developed regions 125 
refer to all regions of Europe, Northern America, Australia/New Zealand and Japan.  Less 126 
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developed regions include all regions of Africa, Asia (excluding Japan), Latin America and the 127 
Caribbean, Melanesia, Micronesia and Polynesia [1]. 128 
For mortality data, we made reference to the WHO mortality data series where data quality 129 
attained criteria of medium level or above [21], representing data with extensive coverage, high 130 
accuracy and completeness. Death certificates acted as the primary data source, and were 131 
compiled by the International Agency for Research on Cancer (IARC).  We adopted age-132 
standardized rate (ASR) using the world standard population [22].   133 
 134 
Statistical Analysis 135 
We employed joinpoint regression analysis to examine the incidence and mortality trends [23].  136 
This technique fits a series of joined straight lines to the trend of ASR [23].  Logarithmic 137 
transformation of the rates was performed with computation of the standard errors based on 138 
binomial approximation.  We specified a maximum number of three joinpoints as analysis 139 
options.  To determine the direction and magnitude of the recent trends, the average annual 140 
percentage change (AAPC) and the respective 95% confidence intervals (C.I.) were evaluated for 141 
the last available 10 years.  The AAPC was calculated as a geometrically weighted average of the 142 
various APCs from the joinpoint regression analysis by the joinpoint trend analysis software, 143 
with weights being equivalent to the length of each segment during the specified time interval 144 
[24].  We reported all data for the incidence and mortality trends in all countries where data were 145 
available. However, the most recent 10 years was chosen as the timeframe for evaluating 146 
temporal trend changes, as was considered a more commonly used time period adopted in 147 
previous publications on global epidemiology of colorectal cancer [13] and breast cancer [25]. In 148 
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describing the temporal trends, the terms increase or decrease was used based on the statistical 149 
significance of AAPC when compared to zero.  Any AAPC with 95% C.Is overlapping with zero 150 
was considered stable, based on the same definition adopted by previous similar studies [13, 25]. 151 
The ASRs were plotted against the HDI and GDP per capita, respectively.  The HDI was divided 152 
into four distinct categories, including low (≤0.534), medium (0.534-0.710), high (0.710-0.796) 153 
and very high (>0.796) [14].  Simple linear regression and correlation coefficients were 154 
employed to examine their associations.   We also assessed whether non-linear associations had 155 
better goodness-of-fit.  All p values<0.05 were regarded as statistically significant. 156 
 157 
 158 
 159 
 160 
 161 
 162 
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 165 
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Results 168 
Incidence and mortality of prostate cancer in 2012 169 
A total of 1.11 million new cases of PCa and 307,500 PCa-related deaths were reported in 2012 170 
(Table 1).  The incidence rates of PCa varied more than 25-fold worldwide in 2012 [1]. The 171 
highest were found in Australia/New Zealand (ASR 111.6 per 100,000), North America (97.2) 172 
and Western Europe (94.4), and the lowest were reported in South-Central Asia (4.5) (Table 1).  173 
Southern Africa (61.8), Western Asia (28.0), North America (97.2), Western Europe (94.4), and 174 
Australia/New Zealand (111.6) were regions where the incidence figures were the most 175 
prominent when compared with other world regions in the same continent.  When compared with 176 
the incidence figures estimated in 2008 [10], a sharp rise was observed in Western Asia (28.0 in 177 
2012 vs. 13.8 in 2008). 178 
PCa mortality rates varied more than 10-fold worldwide in 2012.  Despite the much higher 179 
incidence in more developed than less developed regions (69.5 vs. 14.5), the difference in 180 
mortality figures was comparatively modest (10.0 vs. 6.6).  The highest death rates were reported 181 
in the Caribbean (29.3).  The lowest estimated mortality rates were found for most regions of 182 
Asia (3.8) and Northern Africa (7.0).   183 
 184 
Correlation between incidence/mortality and socioeconomic development 185 
Figure 1a shows the correlation between PCa incidence/mortality and HDI based on simple 186 
linear regression analysis.  The ASR of incidence increased with higher levels of HDI (r=0.58, 187 
p<0.001), whilst the ASR of mortality did not correlate with HDI (r=0.09, p=0.2).  Similarly, 188 
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higher incidence was associated with increasing GDP per capita (r=0.62, p<0.001) but there was 189 
no significant correlation between mortality and GDP per capita (r=0.11, p=0.2) (Figure 1b).  190 
The significant associations between the ASR figures and HDI presented the best goodness-of-fit 191 
when tested for linear relationship. 192 
 193 
Incidence and mortality trends 194 
There were 23 countries with increasing incidence trends, 3 countries with decreasing incidence, 195 
and 10 countries with stable incidence.  There were 5 countries with increasing mortality, 22 196 
countries with decreasing mortality, and 11 countries with stable mortality trends.  We identified 197 
six groups of countries based on their temporal characteristics of incidence and mortality (Table 198 
2; Figure 2; Suppl Figure 1).  These included the below categories: 199 
Group A: increasing incidence and increasing mortality 200 
There were only three countries that reported increase in both incidence and mortality rates 201 
(Figures 3 and 4).  The Philippines, the only country with medium HDI included in this study, 202 
encountered a drastic rise in incidence (AAPC=4.5, 95% C.I. 2.8, 6.3) and mortality 203 
(AAPC=11.4, 95% C.I. 9, 13.9). 204 
Group B: increasing incidence and decreasing mortality 205 
All countries in this group had very high HDI except Brazil.  Among them, the highest incidence 206 
was observed in Brazil (AACP=11.9, 95% C.I. 6.9, 17) and Japan (AAPC=8.8, 95% C.I. 5.9, 207 
11.8).  The reduction in mortality was most marked in France (AAPC=-3.9, 95% C.I. -4.2, -3.6). 208 
 209 
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Group C: increasing incidence and stable mortality 210 
Lithuania (AAPC=21.4, 95% C.I. 16.1, 26.9) reported a very substantial increase in incidence, 211 
followed by Estonia (AAPC=11.1, 95% C.I. 8.4, 13.9). 212 
Group D: stable incidence and decreasing mortality 213 
Most were countries with very high HDI; Canada (AAPC=-3.4, 95% C.I. -3.9, -2.9) and Austria 214 
(AAPC=-3.1, 95% C.I. -3.8, -2.5) experienced the largest decline in mortality rates. 215 
Group E: stable incidence and stable mortality 216 
Three countries has stable trends for both incidence and mortality.  These included Costa Rica, 217 
Iceland, and Malta, with the first nation having high HDI. 218 
Group F: decreasing incidence and decreasing mortality 219 
Three countries that had very high HDI, namely Finland, Sweden and the United States, were 220 
included in this category.  The reduction in incidence and mortality was modest. 221 
 222 
 223 
 224 
 225 
 226 
 227 
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Discussion 228 
This study presented a comprehensive epidemiological analysis of the global profiles of PCa 229 
incidence and mortality based on high quality data.  As of 2012, the Oceania, America and the 230 
European countries followed by Africa suffered from the highest incidence, whilst Asia was the 231 
least affected continent except Western Asia.  The mortality rates paralleled that of the incidence 232 
figures except Africa, where the mortality rate was the highest.  Countries with higher levels of 233 
human development and GDP per capita reported greater incidence but not mortality rates.  The 234 
correlation coefficients of HDI (0.57) and GPD (0.62) for the incidence of PCa were high.   235 
Taking into account the average change of incidence in the previous 10 years, a total of 24 and 5 236 
(out of 36) countries, respectively, experienced increases in incidence and mortality rates.  There 237 
were sharp rises in incidence rates in Europe, Asia and less developed countries in Latin America 238 
and the Caribbean.  Substantially lower mortality rates were observed for the majority of the 239 
countries with time, including Europe, and Northern America.  240 
 241 
Several reasons could explain the wide geographical variations in PCa incidence and its temporal 242 
trends.  Prostate screening, diagnostic ascertainment, and population risk factors have been 243 
attributed as potentially influential factors [11].  An increasing application of transurethral 244 
resection of the prostate and the use of prostate specific antigen (PSA) has likely been affecting 245 
the observed incidence of PCa in many more developed countries [11, 27].  In 1986, the US Food 246 
and Drug Administration has approved its use to monitor disease progression, and late in 1994 247 
endorsed its application for prostate cancer screening among men aged 50 years or above [28].  248 
Other possible influencers of the incidence figures include genetic, lifestyle, and environmental 249 
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factors, but none of them could cause an extremely rapid rise in incidence as observed in most 250 
countries, except prostate screening.  A notable finding consists of the higher incidence of PCa in 251 
Africa, the Caribbean and Brazil, where the majority of the populations consists of Black and 252 
Mulatto individuals.  This might be explained by the modulation of PCa risk via genetic 253 
disposition [30].  Major reasons for the declining mortality trends may include advances in 254 
treatment options for PCa, including radical prostatectomy, hormonal therapy and radiation 255 
therapy [10].  With the more extensive use of PSA to screen for the disease, more early stage 256 
malignancy could be identified and managed in a timely manner.  Nevertheless, some nations 257 
such as the Philippines, the Russian Federation, and Belarus reported significantly increasing 258 
mortality rates.  In particular, the mortality rates in Africa were very high.   These figures might 259 
reflect limited healthcare services and accessibility to early screening and treatment. Another 260 
notable finding which requires future studies includes that countries with high HDI and GDP per 261 
capita were associated with higher incidence, but not with lower mortality of PCa despite better 262 
technology with more screening initiatives. There is a chance that not all countries with high HDI 263 
or GDP may have implemented screening programmes for long enough to allow mortality 264 
reduction to be realized, or that the uptake rate may not have been optimal.  In addition, one of 265 
the possible explanations could be attribution bias due to potentially different healthcare systems 266 
for recording the causes of incidence and mortality. 267 
  268 
This study presented and analyzed the most up-to-date epidemiological data on PCa, yet some 269 
limitations should be addressed.  Firstly, failure or under-reporting of PCa diagnosis could lead to 270 
bias in cancer registration especially in relatively less-developed nations [26].  Figures in regional 271 
cancer registries could be underestimated owing to limited local facilities, and the precision of 272 
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data in these local/regional data is generally lower than that of national data.  On the contrary, in 273 
countries where estimates were based on a single cancer registry in more urbanized, resource 274 
privileged areas, the presented figures could be overestimated if the countries consist of extensive 275 
rural populations.  In addition, only one-third and one-fifth of the world’s countries, respectively, 276 
reported incidence and mortality data of high quality.  The quality of mortality data in terms of 277 
coverage, accuracy, and completeness varies substantially from country to country [29]. Also, the 278 
analysis of relationship between socioeconomic measures and the epidemiological figures could 279 
be confounded by detection and attribution biases, such as that introduced by the inaccuracy of 280 
death certificates and differences in case ascertainment or reporting mechanisms across different 281 
countries. Hence, one might not conclude that there exists a definite correlation between the 282 
incidence/mortality figures and the country-specific socioeconomic development; rather, the 283 
analysis presented a preliminary finding where countries with higher HDI/GDP were found to 284 
have higher PCa incidence.  Lastly, despite our best efforts to analyze the most recent figures, the 285 
data used are from 2012 at the latest and the most contemporary situations will need further 286 
updates. 287 
 288 
Conclusion 289 
The incidence rates of PCa increased in most countries examined in this study, and the mortality 290 
rates declined in most countries, especially in more developed nations.  With population ageing 291 
and population growth, clinicians and policy-makers might expect a further substantial rise in 292 
incidence trends not only attributable to ageing population alone.  The absolute incidence of PCa 293 
will continue to increase much more than the curves in this paper imply. Even in countries with 294 
15 
stable age-standardised incidence and mortality, the number of men diagnosed with and dying of 295 
prostate cancer will substantially increase.  Hence, more healthcare resources are needed to cope 296 
with the treatment of patients diagnosed with PCa, in particular for the more resource-deprived 297 
countries.  Future studies should explore the underlying reasons for these epidemiological trends 298 
as well as the associations between the incidence/mortality figures and other socioeconomic 299 
measures. 300 
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20 
Figure Legends 400 
Figure 1a Correlation between age-standardised prostate cancer incidence (upper panel) and 401 
mortality (lower panel) and Human Development Index (HDI)  402 
Figure 1b Correlation between age-standardised prostate cancer incidence (upper panel) and 403 
mortality (lower panel) and Gross Domestic Product (GDP) 404 
Figure 2 Temporal trends in the incidence and mortality of prostate cancer in the most recent 10 405 
years according to country 406 
Figure 3 The Average Annual Percent Change (AAPC) of prostate cancer incidence in the most 407 
recent 10 years 408 
Figure 4 The Average Annual Percent Change (AAPC) of prostate cancer mortality in the most 409 
recent 10 years 410 
Supplementary Figure 1 Findings from the joinpoint regression analysis of the global incidence 411 
and mortality rates of prostate cancer 412 
 413 
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Table 1 The estimated incidence and mortality of prostate cancer 
according to world area, 2012 
World regions Population size 
(male, thousands) 
Incidence Mortality 
n ASR n ASR 
Africa 549,445 59,493 23.2 42,802 17.0 
Eastern Africa 180,243 17,187 23.3 13,866 18.7 
Middle Africa  69,179 6,892 27.0 5,900 24.2 
Northern Africa 106,147 7,548 10.6 5,000 7.0 
Southern Africa 29,735 10,266 61.7 3,759 24.4 
Western Africa 164,141 17,600 25.1 14,277 21.2 
Asia 2,179,003 196,190 9.4 82,676 3.8 
Eastern Asia 813,296 118,583 10.5 37,553 3.1 
South-Eastern Asia 305,225 26,451 11.2 15,841 6.7 
South-Central Asia 933,786 29,327 4.5 18,860 2.9 
Western Asia 126,697 21,829 28.0 10,422 13.1 
America 303,514 412,739 75.0 85,425 13.1 
Caribbean 20,951 18,719 79.8 7,970 29.3 
Central America 82,227 18,983 28.4 8,957 12.1 
South America 200,336 114,701 60.1 34,386 16.6 
North America 173,209 260,336 97.2 34,112 9.8 
Europe 355,275 400,364 61.3 92,328 11.3 
Central and Eastern 
Europe 
138,249 65,432 31.3 25,862 11.6 
Northern Europe 49,574 81,696 85.0 18,099 14.5 
Southern Europe 74,900 91,355 58.6 20,229 9.1 
Western Europe 92,553 161,881 85.8 28,138 10.7 
Oceania 18,859 26,130 101.9 4,250 13.0 
Australia/New Zealand 13,632 25,296 111.6 3,930 12.9 
Melanesia 4,628 482 22.7 253 13.3 
Micronesia/Polynesia 258 352 72.3 67 13.7 
More developed 
regions* 
604,008 741,966 68.0 142,014 10.0 
Less developed 
regions* 
2,975,297 352,950 14.5 165,467 6.6 
World 3,579,305 1,094,916 30.6 307,481 7.8 
ASR=Age standardized rate per 100,000.  Source: GLOBOCAN 2012 [1].  Numbers are rounded to the 
nearest 10 or 100, and may not add up to the total.  The population size of the world regions were 
retrieved from the Department of Economic and Social Affairs, Population Division, United Nations.  
Available at: http://esa.un.org/unpd/wpp/Download/Standard/Population/  
*More developed regions refer to Europe, Northern America, Australia/New Zealand and Japan.  Less 
developed regions include all regions of Africa, Asia (except Japan), Latin America and the Caribbean 
plus Melanesia, Micronesia and Polynesia. 
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Table 2 Trends in Prostate Cancer incidence and mortality in the most recent 10 
years: six groups of temporal pattern 
Group A: incidence ↑, mortality↑ 
(3 countries) 
Bulgaria, Philippines*, Singapore 
Group B: incidence↑, mortality↓ 
(12 countries) 
Brazil, Czech Republic, France, Ireland, Israel, Italy, Japan, 
Netherlands, Poland, Spain, Switzerland, The United Kingdom 
Group C: Incidence↑, mortality 
stable (8 countries) 
China, Croatia, Estonia, Latvia, Lithuania, Portugal, Slovakia, 
Slovenia  
Group D: Incidence stable,  
mortality↓ (7 countries) 
Australia, Austria, Colombia, Canada, Denmark, New 
Zealand, Norway 
Group E: Incidence stable,  
mortality stable (3 countries) 
Costa Rica, Iceland, Malta 
Group F: incidence ↓, mortality↓ 
(3 countries) 
Finland, Sweden, United States 
*Medium Human Development Index (HDI); High HDI.  All remaining countries had very high HDI. 
(Low HDI refers to HDI ≤ 0.534; Medium HDI refers to 0.534 < HDI ≤ 0.710; High HDI refers to 0.710 < 
HDL ≤ 0.796; and Very high HDL refers to HDI > 0.796) 
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Figure 1a Correlation between age-standardised prostate cancer incidence 
(upper panel) and mortality (lower panel) and Human Development Index 
(HDI)  
 
r = 0.58 
r = 0.092 
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Figure 1b Correlation between age-standardized prostate cancer incidence 
(upper panel) and mortality (lower panel) and Gross Domestic Product (GDP) 
 
 
 
r = 0.62 
r = 0.11 
25 
Figure 2 Temporal trends in the incidence and mortality of prostate cancer in 
the most recent 10 years according to country 
Group A: Increasing incidence and mortality 
 
 
 
 
 
 
 
 
 
 
 
 
 
Group B: Increasing incidence and decreasing mortality  
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Group C: Increasing incidence and stable mortality 
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Group D: Stable incidence and decreasing mortality 
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Group E: Stable incidence and mortality 
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Group F: Decreasing incidence and mortality 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
All figures were expressed as Age-standardized rate (ASR) per 100,000.  The blue line refers to 
incidence and red line refers to mortality.  All data for incidence and mortality were retrieved 
from the Cancer Incidence in Five Continents series I-V and the WHO mortality database, 
respectively, except for US, Australia, New Zealand, Bulgaria, Ireland, Portugal, Denmark, 
Finland, Iceland, Norway, Sweden where country-specific registries were used as more 
comprehensive and updated data were available [16-20]. 
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Figure 3 The Average Annual Percentage Change (AAPC) of prostate cancer 
incidence in the most recent 10 years 
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Figure 4 The Average Annual Percentage Change (AAPC) of prostate cancer 
mortality in the most recent 10 years 
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Supplementary Figure 1 Findings from the joinpoint regression analysis of the global 
incidence and mortality rates of prostate cancer 
(A). Incidence 
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(B) Mortality 
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